|1.||Schwarz, Stefan: 5 articles (01/2014 - 12/2010)|
|2.||Csuk, René: 5 articles (01/2014 - 12/2010)|
|3.||Yuan, Zhi: 4 articles (10/2014 - 11/2011)|
|4.||Wang, Wei: 4 articles (10/2014 - 11/2011)|
|5.||Ströhl, Dieter: 4 articles (03/2012 - 12/2010)|
|6.||Kluge, Ralph: 4 articles (03/2012 - 12/2010)|
|7.||Ke, Xue: 3 articles (01/2015 - 06/2012)|
|8.||Cheng, Mingrong: 3 articles (01/2014 - 01/2013)|
|9.||Chen, Houxiang: 3 articles (01/2014 - 01/2013)|
|10.||Zhang, Zhiping: 3 articles (01/2014 - 01/2013)|
11/01/2011 - "With further studies on mechanism of anticancer actions, glycyrrhetinic acid is being expected to have a good prospect of development and application for cancer therapy."
07/01/2011 - "The present study was designed to extend our previous study on the c-Ha-ras and c-myc-induced tumor cell-selective antiproliferative effects of a licorice component, glycyrrhetinic acid (GA). "
01/01/2005 - "In the present study, we found that glycyrrhetinic acid inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA) mediated oxidative stress and tumor promotion in murine skin. "
01/01/2014 - "Synthesis of novel 2-cyano substituted glycyrrhetinic acid derivatives as inhibitors of cancer cells growth and NO production in LPS-activated J-774 cells."
03/01/2012 - "Its aglycon, glycyrrhetinic acid, has many biological activities, among them a pronounced cytotoxicity against tumor cells. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
09/01/2005 - "[Targeting glycyrrhetinic acid to hepatic stellate cells in treating rat liver fibrosis]."
08/01/2004 - "[Targeted glycyrrhetinic acid to receptors of hepatic stellate cells for the treatment of rat liver fibrosis: a pilot study]."
12/01/1995 - "On the other hand, the concentration of the glycyrrhetic acid was kept higher in the patients with liver cirrhosis than that of chronic hepatitis, but there were no significant difference between them except for after a half hour from the administration. "
01/01/2013 - "The protective effect of glycyrrhetinic acid on carbon tetrachloride-induced chronic liver fibrosis in mice via upregulation of Nrf2."
02/01/2001 - "Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats."
|3.||Liver Neoplasms (Liver Cancer)
03/02/2015 - "Due to overexpression of glycyrrhetinic acid (GA) receptor in liver cancer cells, glycyrrhetinic acid modified recombinant human serum albumin (rHSA) nanoparticles for targeting liver tumor cells may result in increased therapeutic efficacy and decreased adverse effects of cancer therapy. "
03/02/2015 - "In this study, doxorubicin (DOX) loaded and glycyrrhetinic acid modified recombinant human serum albumin nanoparticles (DOX/GA-rHSA NPs) were prepared for targeting therapy for liver cancer. "
01/01/2014 - "Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells [Retraction]."
09/01/2013 - "Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo."
01/01/2013 - "Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells."
01/01/1991 - "Anti-hepatitis effect of the olean-9(11),12-diene-3 b, 30-diol 3 b, o-hemisuccinate Na Salt (III b), a glycyrrhetinic acid derivative, was studied in CCl4 induced mouse. "
01/01/1991 - "Effect of olean-9(11), 12-diene-3 beta, 30-diol 3 beta, o-hemisuccinate Na salt, a glycyrrhetinic acid derivative, on peroxidation in CCl4 induced mouse acute hepatitis."
04/01/2004 - "Glycyrrhetic acid-loaded microparticles: liver-specific delivery and therapeutic potential against carbon tetrachloride-induced hepatitis."
10/01/2011 - "Glycyrrhetinic acid (GA) is an active component of licorice root that has long been used as a herbal medicine for the treatment of peptic ulcer, hepatitis, and pulmonary and skin diseases in Asia and Europe. "
01/01/2003 - "GL is one of the leading natural compounds for clinical trials of chronic active viral hepatitis and HIV infections (preparation Stronger Neo-Minophagen C, SNMC), and its monoammonium salt (glycyram, tussilinar) is used as an anti-inflammatory and anti-allergic remedy. "
01/01/2011 - "A new approach in the first-line treatment of bacterial and mycotic vulvovaginitis with topical lipohydroperoxides and glycyrrhetic acid: a comparative study."
01/01/2011 - "Topical medication based on lipohydroperoxides and glycyrrhetic acid showed a clinical and microbiological efficacy in the first-line treatment of bacterial and mycotic vulvovaginitis, comparable to conventional drugs."
01/01/2011 - "PURPOSE OF INVESTIGATIONS: The aim of this randomized controlled trial was to evaluate efficacy and tolerability of a new association of lipohydroperoxides and glycyrrhetic acid on topical treatment of bacterial and mycotic vulvovaginitis. "
01/01/2011 - "One hundred consecutive patients with bacterial or mycotic vulvovaginitis were randomly assigned to a study group treated with vaginal lipohydroperoxides and a derivative of glycyrrhetic acid for three days (n = 50), and a control group using vaginal antibacterial metronidazole (500 mg) or antimycotic econazole (150 mg) for six days (n = 50). "
|1.||Carbon Tetrachloride (Tetrachloromethane)
|3.||Transcription Factors (Transcription Factor)
|10.||Dimethyl Sulfoxide (DMSO)
|1.||Drug Therapy (Chemotherapy)